Presentation
7 March 2022 PARP1 as a biomarker towards in vivo multimodal melanoma diagnosis
Aditi Sahu, Ucalene Harris, Melissa Gill, Cecelia Lezcano, Allan Halpern, Anthony Rossi, Klaus Busam, Thomas Reiner, Ashfaq Marghoob, Manu Jain, Milind Rajadhyaksha
Author Affiliations +
Abstract
Melanoma is the most aggressive skin cancer with the highest associated mortality, early diagnosis ensures high survival rates. Currently, in vivo morphological imaging such as reflectance confocal microscopy (RCM) is associated with high sensitivity but moderate specificity. Addition of molecular imaging using PARPi-FL (PARP1-targeted fluorophore) can improve distinction between malignant/potentially malignant lesions. Towards multimodal imaging in vivo, we first investigated differential PARP1 expression in the spectrum of melanocytic lesions. Higher PARP area positivity and intensity were found in melanoma as compared to benign nevi. Thus, PARPi-FL in association with RCM can potentially improve melanoma diagnosis non-invasively in patients.
Conference Presentation
© (2022) COPYRIGHT Society of Photo-Optical Instrumentation Engineers (SPIE). Downloading of the abstract is permitted for personal use only.
Aditi Sahu, Ucalene Harris, Melissa Gill, Cecelia Lezcano, Allan Halpern, Anthony Rossi, Klaus Busam, Thomas Reiner, Ashfaq Marghoob, Manu Jain, and Milind Rajadhyaksha "PARP1 as a biomarker towards in vivo multimodal melanoma diagnosis", Proc. SPIE PC11943, Molecular-Guided Surgery: Molecules, Devices, and Applications VIII, PC1194309 (7 March 2022); https://doi.org/10.1117/12.2610476
Advertisement
Advertisement
KEYWORDS
Melanoma

In vivo imaging

Molecular imaging

Cancer

Confocal microscopy

Reflectivity

Skin cancer

Back to Top